Laboratory of Molecular Microbiology,
National Institute of Allergy and Infectious Diseases,
Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases
Yoshiaki Nishimura has not added Biography.
If you are Yoshiaki Nishimura and would like to personalize this page please email our Author Liaison for assistance.
Loss of naïve cells accompanies memory CD4+ T-cell depletion during long-term progression to AIDS in Simian immunodeficiency virus-infected macaques.
Journal of virology Jan, 2007 | Pubmed ID: 17093193
Short- and long-term clinical outcomes in rhesus monkeys inoculated with a highly pathogenic chimeric simian/human immunodeficiency virus.
Journal of virology Aug, 2000 | Pubmed ID: 10888632
Rapid and irreversible CD4+ T-cell depletion induced by the highly pathogenic simian/human immunodeficiency virus SHIV(DH12R) is systemic and synchronous.
Journal of virology Jan, 2002 | Pubmed ID: 11739702
Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies.
Journal of virology Mar, 2002 | Pubmed ID: 11836389
Amino acid deletions are introduced into the V2 region of gp120 during independent pathogenic simian immunodeficiency virus/HIV chimeric virus (SHIV) infections of rhesus monkeys generating variants that are macrophage tropic.
Proceedings of the National Academy of Sciences of the United States of America Oct, 2002 | Pubmed ID: 12370415
Early control of highly pathogenic simian immunodeficiency virus/human immunodeficiency virus chimeric virus infections in rhesus monkeys usually results in long-lasting asymptomatic clinical outcomes.
Journal of virology Oct, 2003 | Pubmed ID: 14512533
Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development.
Proceedings of the National Academy of Sciences of the United States of America Dec, 2003 | Pubmed ID: 14627745
Highly pathogenic SHIVs and SIVs target different CD4+ T cell subsets in rhesus monkeys, explaining their divergent clinical courses.
Proceedings of the National Academy of Sciences of the United States of America Aug, 2004 | Pubmed ID: 15297611
Resting naive CD4+ T cells are massively infected and eliminated by X4-tropic simian-human immunodeficiency viruses in macaques.
Proceedings of the National Academy of Sciences of the United States of America May, 2005 | Pubmed ID: 15911767
CD8+ and CD20+ lymphocytes cooperate to control acute simian immunodeficiency virus/human immunodeficiency virus chimeric virus infections in rhesus monkeys: modulation by major histocompatibility complex genotype.
Journal of virology Dec, 2005 | Pubmed ID: 16282488
Although macrophage-tropic simian/human immunodeficiency viruses can exhibit a range of pathogenic phenotypes, a majority of isolates induce no clinical disease in immunocompetent macaques.
Journal of virology Oct, 2007 | Pubmed ID: 17626082
Association of progressive CD4(+) T cell decline in SIV infection with the induction of autoreactive antibodies.
PLoS pathogens Apr, 2009 | Pubmed ID: 19360097
High frequencies of resting CD4+ T cells containing integrated viral DNA are found in rhesus macaques during acute lentivirus infections.
Proceedings of the National Academy of Sciences of the United States of America May, 2009 | Pubmed ID: 19416840
Noninvasive in vivo imaging of CD4 cells in simian-human immunodeficiency virus (SHIV)-infected nonhuman primates.
Blood Jul, 2009 | Pubmed ID: 19417212
Initiation of antiretroviral therapy 48 hours after infection with simian immunodeficiency virus potently suppresses acute-phase viremia and blocks the massive loss of memory CD4+ T cells but fails to prevent disease.
Journal of virology Jul, 2009 | Pubmed ID: 19420078
Neutralizing antibody titers conferring protection to macaques from a simian/human immunodeficiency virus challenge using the TZM-bl assay.
AIDS research and human retroviruses Jan, 2010 | Pubmed ID: 20059398
Generation of the pathogenic R5-tropic simian/human immunodeficiency virus SHIVAD8 by serial passaging in rhesus macaques.
Journal of virology May, 2010 | Pubmed ID: 20147396
Recombination-mediated changes in coreceptor usage confer an augmented pathogenic phenotype in a nonhuman primate model of HIV-1-induced AIDS.
Journal of virology Oct, 2011 | Pubmed ID: 21813599
The acute HIV infection: implications for intervention, prevention and development of an effective AIDS vaccine.
Current opinion in virology Sep, 2011 | Pubmed ID: 21909345
The simian immunodeficiency virus targets central cell cycle functions through transcriptional repression in vivo.
PloS one , 2011 | Pubmed ID: 22043290
Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque.
Proceedings of the National Academy of Sciences of the United States of America Dec, 2011 | Pubmed ID: 22123961
Pathogenicity and mucosal transmissibility of the R5-tropic simian/human immunodeficiency virus SHIV(AD8) in rhesus macaques: implications for use in vaccine studies.
Journal of virology Aug, 2012 | Pubmed ID: 22647691
Most rhesus macaques infected with the CCR5-tropic SHIV(AD8) generate cross-reactive antibodies that neutralize multiple HIV-1 strains.
Proceedings of the National Academy of Sciences of the United States of America Nov, 2012 | Pubmed ID: 23129652
Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization.
Science (New York, N.Y.) May, 2013 | Pubmed ID: 23661761
Emergence of gp120 V3 variants confers neutralization resistance in an R5 simian-human immunodeficiency virus-infected macaque elite neutralizer that targets the N332 glycan of the human immunodeficiency virus type 1 envelope glycoprotein.
Journal of virology Aug, 2013 | Pubmed ID: 23720719
Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia.
Nature Nov, 2013 | Pubmed ID: 24172896
Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques.
The Journal of experimental medicine Sep, 2014 | Pubmed ID: 25155019
Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants.
The Journal of experimental medicine Nov, 2014 | Pubmed ID: 25385756
Analysis of immunoglobulin transcripts and hypermutation following SHIV(AD8) infection and protein-plus-adjuvant immunization.
Nature communications , 2015 | Pubmed ID: 25858157
The Expression of Functional Vpx during Pathogenic SIVmac Infections of Rhesus Macaques Suppresses SAMHD1 in CD4+ Memory T Cells.
PLoS pathogens May, 2015 | Pubmed ID: 25996507
Quality and quantity of TFH cells are critical for broad antibody development in SHIVAD8 infection.
Science translational medicine Jul, 2015 | Pubmed ID: 26223303
A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges.
Nature May, 2016 | Pubmed ID: 27120156
Early antibody therapy can induce long-lasting immunity to SHIV.
Nature Mar, 2017 | Pubmed ID: 28289286
Of Mice, Macaques, and Men: Broadly Neutralizing Antibody Immunotherapy for HIV-1.
Cell host & microbe Aug, 2017 | Pubmed ID: 28799906
A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection.
Nature medicine May, 2018 | Pubmed ID: 29662199
Immunotherapy during the acute SHIV infection of macaques confers long-term suppression of viremia.
The Journal of experimental medicine Jan, 2021 | Pubmed ID: 32966579
A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-Glycan patch.
eLife Oct, 2020 | Pubmed ID: 33084569
Concordance of immunological events between intrarectal and intravenous SHIVAD8-EO infection when assessed by Fiebig-equivalent staging.
The Journal of clinical investigation Sep, 2021 | Pubmed ID: 34623326
Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env.
Science translational medicine Nov, 2021 | Pubmed ID: 34818054
Harald Hartweger1,
Rajeev Gautam2,
Yoshiaki Nishimura2,
Fabian Schmidt3,5,
Kai-Hui Yao1,
Amelia Escolano1,6,
Mila Jankovic1,
Malcolm A. Martin2,
Michel C. Nussenzweig1,4
1Laboratory of Molecular Immunology, The Rockefeller University,
2Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health,
3Laboratory of Retrovirology, The Rockefeller University,
4Howard Hughes Medical Institute, The Rockefeller University,
5Laboratory of Applied Virology and Precision Medicine, King Abdullah University of Science and Technology (KAUST),
6Vaccine and Immunotherapy Center, Wistar Institute
JoVE Hakkında
Telif Hakkı © 2020 MyJove Corporation. Tüm hakları saklıdır